Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487952 | 1.00 | EPHX2 (0.46) | EPHX2CA1CA2HSD17B10L3MBTL1 | |
| SCHEMBL11148891 | 0.73 | EPHX2 (0.50) | EPHX2CA1CA2HSD17B10L3MBTL1 | |
| SCHEMBL1072726 | 0.73 | EPHX2 (0.50) | EPHX2CA1CA2HSD17B10L3MBTL1 | |
| Hydrochloric Acid SCHEMBL11156725 | 0.71 | EPHX2 (0.48) | EPHX2CA1CA2HSD17B10L3MBTL1 | |
| SCHEMBL387316 | 0.69 | CYP2C9 (0.44) | EPHX2CA1CA2CYP2C9HSD11B1 | |
| SCHEMBL15892084 | 0.69 | EPHX2 (0.41) | EPHX2CA1CA2HSD17B10L3MBTL1 | |
| SCHEMBL630318 | 0.69 | SMN1; SMN2 (0.42) | EPHX2CA1CA2HSD17B10L3MBTL1 | |
| SCHEMBL1502375 | 0.69 | CA1 (0.48) | EPHX2CA1CA2HSD17B10L3MBTL1 | |
| SCHEMBL12408108 | 0.69 | EPHX2 (0.46) | EPHX2CA1CA2HSD17B10L3MBTL1 | |
| SCHEMBL7672245 | 0.69 | EPHX2 (0.52) | EPHX2CA1CA2HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7803839-B2 | anticarcinogenic agent; 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-carbonyl)azetidin-3-ol | EXELIXIS, INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | EPHX2 908/4885CA1 1855/4885CA2 735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.